Cytotoxic T cell (CTL) assay with Keytruda (anti-PD1) – IMMUNE 3D

$10,000.00

Description

The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. IMMUNE 3D® is a physiologically relevant platform that is designed to capture the immune-tumor interactions in the presence of tumor environment cells.  This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 24 well format.

What is the assay setup?

  1. Co-culture tumor and CTL for 6 days in the presence of drug candidate
  2. After 6 days harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. CTL + Tumor+ Tecentriq (anti-PDL1)
  2. CTL + Tumor+ <drug candidate (per dose)>
  3. CTL + Tumor
  4. CTL + Tumor + DMSO
  5. CTL
  6. Tumor

How many doses are included?

The assay is run in a 24 well plate and can accommodate up to 7 doses of the drug candidate. Each dose is a well. Each dose is run in duplicates (2 times)

What readouts are included in the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Lactate dehyrdogenase (LDH)  for tumor lysis
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Combination arm

Include study arms in combination with Keytruda (anti-PD1)

Flow cytometry

Study expression markers on CTL and tumors in response to drug candidates.

Imaging

Image the 3D cultures at various time points to observe tumor lysis

Description

 

 

 

 

You may also like…